ClinicalTrials.gg
CompletedNCT00851734Updated Jun 22, 2012

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

A Phase 1 interventional study of voclosporin ophthalmic solution in Keratoconjunctivitis Sicca, sponsored by Lux Biosciences, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-22.

Sponsored by Lux Biosciences, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Keratoconjunctivitis Sicca with a site in United States — none open to participants now, none under way, none of them phase 3. Keratoconjunctivitis Sicca · United States.

Enrollment
36th of 52
35 · median 100
Started
2009
with 2 others
Phase 1
2 of 56
none open now
Registered
14th of 56
by date

Among the 56 studies in Keratoconjunctivitis Sicca with a site in United States, this one is the 36th largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2009, is one of 2 in phase 1, and was the 14th registered.

Keratoconjunctivitis Sicca

85 studies on the registry are indexed under Keratoconjunctivitis Sicca; 1 is open to participants now.

Browse Keratoconjunctivitis Sicca studies →

Open to participants now

None of the 56 studies in Keratoconjunctivitis Sicca with a site in United States is open now. The open studies under Keratoconjunctivitis Sicca, anywhere →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 56 studies in Keratoconjunctivitis Sicca with a site in United States as a file.
02

Study summary

This is a first-in-man study for the purpose of determining the safety and tolerability of LX214 ophthalmic solution in healthy volunteers and in patients with dry eye syndrome.

03

Conditions studied

  • Keratoconjunctivitis Sicca
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No systemic disease as determined by a physical examination, clinical laboratory evaluation, and an
  • Schirmer's I Test ≥ 10mm/5 minutes with anesthesia
  • Corrected Snellen acuity of 20/40 or better in both eyes

Exclusion criteria

Exclusion Criteria:

  • Subjects diagnosed with any ocular disease other than refraction error
  • Subjects with intraocular pressure >21 mmHg
  • Use of a contact lens within 7 days prior to administration of the first dose
  • Subjects with history of ocular surgery
  • Subjects with a history of laser refractive surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    LX214 0.02%

    LX214 ophthalmic solution 0.02%

    Drug: voclosporin ophthalmic solution

  • Experimental
    LX214 0.2%

    Drug: voclosporin ophthalmic solution

  • Placebo comparator
    placebo

    placebo

    Drug: voclosporin ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. ocular irritation

    Time frame: 12 hours

07

Study locations

1 site
  • Product Investigations
    Conshohocken, Pennsylvania 19428, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Mar 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2009
First posted
Feb 26, 2009
Start
Feb 2009
Primary completionActual
Mar 2009
CompletionActual
Apr 2009
Last update
Jun 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00851734
Lead sponsor
Lux Biosciences, Inc.
Responsible party
Sponsor
First posted
Feb 26, 2009
Start date
Feb 2009
Primary completion
Mar 2009
Completion
Apr 2009
Last update
Jun 22, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion